Renal Disease Treatments: Products and Therapies

Description:

This report provides:

- An in-depth analysis of the market for kidney failure treatment products and services, forecasting growth and trends in various sectors.

- Analyses of market trends, with data from 2015, 2016, and projections of compound annual growth rates (CAGRs) through 2021.

- Detailed coverage of products and services including those for treating acute renal failure, chronic renal failure, and end-stage renal disease, the final phase of chronic kidney failure.

- Specific segmentation of the market into pharmaceuticals used to address the conditions associated with kidney failure (i.e., hypertension, diabetes, and anemia); hemodialysis and peritoneal dialysis products and services; and surgical procedures used to keep the end-stage kidney patient alive (i.e., surgeries to create vascular access sites for dialysis, and kidney transplantation).

- Evaluation of the industry structure and dynamics, as well as technological developments.

- Profiles of major players in the industry.

Five-year projections for market activity and value are provided. Treatment types and trends for acute and chronic kidney failure, pricing considerations for medications, dialysis products (dialysis machines, dialysates and dialyzers) and therapies, and surgical procedures, companies, industry structure, and participating companies are included in the study.

Breakdowns:

- Therapeutic products
  - Anemia
  - Diabetic nephropathy
  - Hyperkalemia
  - Hypertension

- Renal replacement therapy
  - Hemodialysis
  - - Intermittent hemodialysis
  - - Continuous renal replacement therapy (CRRT)
  - Peritoneal
  - - Continuous ambulatory peritoneal dialysis (CAPD)
  - - Continuous cycling peritoneal dialysis (CCPD)

- Renal transplantation

Other related topics discussed include the diagnosis criteria, leading pharmaceutical companies and the competitive landscape. The market analysis is based on the regional, demographic and treatment options.

The report includes analysis of leading and emerging competitors in the current worldwide diagnostic market for kidney diseases. Profiles of manufacturers of leading products as well as biotechnology companies with products in development are discussed, along with their specific product strategies. Detailed profiles of current market leaders are included, as well as profiles of companies with innovative products poised to advance within the forecast period.

Market figures are based on revenues at the manufacturers' level and are projected at 2016-dollar value. Inflation is not computed into projection figures. Trends are assessed based on projected sales for existing products, new product introductions, expanded indications for existing products and projected changes in the prevalence of diagnosis for respective diseases. In addition, the report includes forecasts by product,
product category and company from 2014 through 2021. The study is arranged to offer an overview of the diagnostic market accompanied by product, company and region.

Excluded from this report are treatments for the less-common kidney diseases, including polycystic kidney disease, Immunoglobulin A (IgA) nephropathy, nephrotic syndrome and minimal change disease. Sales figures are reported in U.S. dollars and in each case reflect currency fluctuations within the performance of sales change. Sales figures do not account for variation in local currencies. All market share data presented are on a global basis unless specifically noted.

Contents:

1: Introduction
- Study Goals And Objectives
- Reasons For Doing The Study
- Scope Of Report
- Intended Audience
- Methodology And Information Sources
- Disclaimer

2: Summary
- Table Summary : The U.S. Market For Kidney Disease Treatment, Through 2021
- Figure Summary : The U.S. Market For Kidney Disease Treatment, 2015-2021

3: Kidney Disease Overview
- Kidney Function
- Renal Disease
- Symptoms
- Classification Of Kidney Injury And Disease
- Relationship Between Acute Kidney Injury And Chronic Kidney Disease
- Connection Between Cardiovascular And Renal Disease
- Epidemiology
- Hospitalization From Kidney Disease
- The Economic Budren And Coverage Of Kidney Disease
- Medicare's Esrd Program

4: Acute Kidney Disease Overview
- Prerenal Causes
- Intrinsic Renal Causes
- Postrenal Causes
- Epidemiology
- Diagnosis
- Novel Aki Biomarker
- Hospitalization In Patients With Acute Kidney Disease
- Aki Prevalence
- Figure 5 : Classification Of Acute Kidney Injury

5: Treatment For Acute Kidney Disease
- Pharmaceuticals Used In Acute Kidney Injury
- Acute Renal Replacement Therapy
- Economics Of Aki
- The U.S. Market For Treating Aki

6: Chronic Kidney Disease
- Overview
- Epidemiology Of Renal Disease
- Cause Of Chronic Kidney Disease
- Number Of Individuals With Ckd
- Hospitalization And Mortality In Patients With Chronic Kidney Disease
- Ckd Trends In The World
- Costs Of Chronic Kidney Disease

7: Pharmaceutical Therapy Strategy And Market For Chronic Kidney Disease
- Drug Prescribing In Chronic Kidney Disease
- Pharmaceutical Therapies
Table 16: Prevalence Of CKD In NHANES Population Within Age, Sex, Race/Ethnicity And Risk-Factor Categories, 1998-2012
Table 17: Unadjusted And Adjusted All-Cause Hospitalization Rates For Medicare Patients Aged 66 And Older By CKD Status, 2012
Table 18: Incidence Of ESRD By Country, 2013
Table 19: Prevalence Of ESRD By Country, 2013
Table 20: Top Ten Countries Having The Highest % Rise In ESRD Incidence Rate Plus The U.S., 2001 And 2013
Table 21: Five Countries Having The Largest % Decline In ESRD Incidence Rate, 2001 And 2013
Table 22: Percentage Of Incident ESRD Patients Due To Diabetes By Country, 2013
Table 23: Prevalence Of Hypertension And Dyslipidemia By CKD Stage
Table 24: The Commonly Prescribed Class Of Medication In Chronic Kidney Disease Patients
Table 25: Recommended Antihypertensive Agents For Patients With Chronic Kidney Disease And Hypertension
Table 26: Commonly Prescribed ACE Inhibitors: Brand Name, Generic Name And Manufacturer
Table 27: Commonly Prescribed Angiotensin Receptor Blockers: Brand Name, Generic Name And Manufacturer
Table 28: Commonly Prescribed Beta Blockers: Brand Name, Generic Name And Manufacturer
Table 29: Commonly Prescribed Calcium Channel Blockers: Brand Name, Generic Name And Manufacturer
Table 30: List Of Antihyperkalemia Medication In Development: Brand Name, Generic Name, Manufacturer And Clinical Stage
Table 31: Commonly Prescribed Phosphate Binder: Brand Name, Generic Name And Manufacturer
Table 32: Commonly Prescribed Statin: Brand Name, Generic Name And Manufacturer
Table 33: Commonly Prescribed Bile Acid Sequestrants: Brand Name, Generic Name And Manufacturer
Table 34: Commonly Prescribed Fibrates: Brand Name, Generic Name And Manufacturer
Table 35: Commonly Prescribed Diuretics: Brand Name, Generic Name And Manufacturer
Table 36: Commonly Prescribed Erythropoiesis-Stimulating Agents: Brand Name, Generic Name And Manufacturer
Table 37: List Of HIF-Ph Inhibitors In The Development: Manufacturer And Respective Clinical Stage
Table 38: Commonly Prescribed Iron Supplement: Brand Name, Generic Name And Manufacturer
Table 39: Commonly Prescribed Glucose Management: Brand Name, Generic Name And Manufacturer
Table 40: List Of Novel Agent For Treating Diabetic Nephropathy: Manufacturer And Respective Clinical Stage
Table 41: Commonly Prescribed Medication For Chronic Kidney Disease: Brand Name, Generic Name And Manufacturer
Table 42: Commonly Prescribed Immunosuppressant Drugs: Brand Name, Generic Name And Manufacturer
Table 43: Immunosuppression Maintenance Regimen At Discharge And 1 Year After Transplant, 2006
Table 44: Immunosuppression Drug Use, Induction Drugs, At Discharge, At One Year Posttransplant, 2005 And 2006
Table 45: Factor Linked With Noncompliance In Chronic Disease
Table 46: Costs Of Commonly Used Prescription Drugs For Treating Renal Failure And Associated Diseases
Table 47: The U.S. Market For Pharmaceuticals Used In Chronic Kidney Disease Treatment By Type, Through 2021
Table 48: Common Drug Classes Used By Part D-Enrolled Dialysis Patients, By Percentage Of Patients, Drug Class, 2013
Table 49: Comparison Of 2008 And 2012-Based ESRD Market Basket Cost Categories And Weights
Table 50: Market Share Of Overall Dialysis Products, 2014
Table 51: Dialysate Products For HD, PD And CRRT
Table 52: Peritoneal Dialysis Systems, Type And Manufacturer
Table 53: Peritoneal Dialysis Equipment Market Share By Manufacturer, 2014
Table 54: The U.S. Market For ESRD Treatment By Type, Through 2021
Table 55: The U.S. ESRD Population By Treatment Type, 2010-2021
Table 56: The U.S. ESRD Population By Treatment Type, 2010-2021
Table 57: Costs For Common Dialysis Equipment, HD, PD And CRRT
Table 58: Market Share Of Hemodialysis Products, 2014
Table 59: Commercial Dialysis Systems And Manufacturers
Table 60: The U.S. Market For Dialysis Systems By Type, Through 2021
Table 61: The U.S. Market For Major Dialysis Consumables By Type, Through 2021
Table 62: Dialysis Patients Counts By Unit Affiliation, 2010-2013
Table 63: Dialysis Center In The U.S., 2010-2013
Table 64: Distribution Of Type Of Vascular Access In Use Among Prevalent Hemodialysis Patients In 2013, From Crownweb Data, December 2013
Table 65: Unadjusted Kidney Transplant Rates, All Donor Types By Age, Sex, Race And Primary Cause Of ESRD, Per 100 Dialysis Patient Years, 2004-2013
Table 66: Vascular Access Use at Hemodialysis Initiation
Table 67: The U.S. Market for Surgical Procedures Used in Renal Failure Treatment by Type, Through 2021
Table 68: Estimated U.S. Average Billed Charges per Organ Transplant, 2011

List of Figures

Summary Figure: The U.S. Market for Kidney Disease Treatment, 2015-2021
Figure 1: Renal Status One Year Following Discharge from AKI Hospitalization among Medicare Patients Aged 66+, 2010-2011
Figure 2: Potential Outcome of Acute Kidney Injury
Figure 3: Cardiovascular Disease in Patients with or Without CKD, 2012
Figure 4: Trends of Kidney Disease Incident Rate in the U.S., 1980-2005
Figure 5: Classification of Acute Kidney Injury
Figure 6: Treatment Flowchart for Acute Kidney Injury
Figure 7: Number of Hospitalizations with Acute Kidney Injury, 1979-2002
Figure 8: Schematic of Continuous Renal Replacement Therapy
Figure 9: Schematic of Different Types of CRRT
Figure 10: Schematic Representation of the Mechanisms Underlying Anemia of CKD
Figure 11: Recognized Molecular Mechanisms Involved in Pathogenesis of Diabetic Kidney Disease
Figure 12: Mechanisms of Phosphate Homeostasis
Figure 13: CKD Patients Aware of Their Kidney Disease, 2001-2012
Figure 14: Prevalence of CKD by Stage among NHANES Participants, 1988-2012
Figure 15: Trends in Number of Prevalent ESRD Cases in the U.S. Population by Age Group, 1996-2013
Figure 16: Adjusted All-Cause Hospitalization Rates for Medicare Patients Aged 66 and Older by CKD Status and Stage, 2012
Figure 17: Adjusted All-Cause Hospitalization Rates in Medicare Patients Aged 66 and Older, by Race, CKD Status and Stage, 2012
Figure 18: Unadjusted and Adjusted All-Cause Mortality Rate for Medicare Patients
Figure 19: Immunosuppression Use in Pediatric Kidney Transplant Recipients
Figure 20: Mechanisms of Solute Removal in Dialysis
Figure 21: Trends in the Number of Incident Cases of ESRD in the U.S. Population by Modality, 1980-2012
Figure 22: Schematic of the Hemodialysis Membrane
Figure 23: Schematic of Typical Hemodialysis System
Figure 24: Continuous Ambulatory Peritoneal Dialysis
Figure 25: Schematic for Artificial Kidney
Figure 26: Forearm AV Fistula
Figure 27: AV Graft
Figure 28: Venous Catheter
Figure 29: Trends in Vascular Access Type Use among ESRD Prevalent Patients, 2003-2014
Figure 30: Tenckhoff Catheters
Figure 31: Percentage of Dialysis Patients Wait-Listed and Unadjusted Kidney Transplant Rates, 1996-2013
Figure 32: Percentage of Incident Patients Being Wait-Listed or Receiving a Kidney Transplant Within One Year of ESRD Initiation by Age, 1996-2012
Figure 33: Number of Kidney Transplants, 1996-2013
Figure 34: Data on Age, Sex, Race, and Primary Cause of Disease among Kidney Transplant, 1998-2012
Figure 35: Outcomes in Adult Kidney Transplant Recipients: A) Deceased Donor, B) Living Donor
Figure 36: Medicare Coverage among Kidney Transplant Recipients
Figure 37: Vadadustat Clinical Development
Figure 38: Ardelyx Pipeline Overview
Figure 39: Roxadustat Development Timeline
Figure 40: Noxxon Pipeline Overview

Ordering:
Order Online - http://www.researchandmarkets.com/reports/3768822/
Order by Fax - using the form below
Order by Post - print the order form below and send to
Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

Product Name: Renal Disease Treatments: Products and Therapies
Web Address: http://www.researchandmarkets.com/reports/3768822/
Office Code: SCH3G81T

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Quantity</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF) - Single User:</td>
<td>USD 5985</td>
</tr>
<tr>
<td>Electronic (PDF) - 1 - 5 Users:</td>
<td>USD 7650</td>
</tr>
</tbody>
</table>

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title: [ ] Mr [ ] Mrs [ ] Dr [ ] Miss [ ] Ms [ ] Prof
First Name: ___________________________ Last Name: ___________________________
Email Address: * ___________________________
Job Title: ___________________________
Organisation: ___________________________
Address: ___________________________
City: ___________________________
Postal / Zip Code: ___________________________
Country: ___________________________
Phone Number: ___________________________
Fax Number: ___________________________

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer: Please transfer funds to:
Account number 833 130 83
Sort code 98-53-30
Swift code ULSBIE2D
IBAN number IE78ULSB98533083313083
Bank Address Ulster Bank,
27-35 Main Street,
Blackrock,
Co. Dublin,
Ireland.

If you have a Marketing Code please enter it below:

Marketing Code: 

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp